Levamlodipine/telmisartan - Chong Kun Dang
Alternative Names: CKD-345; CKD-828; CKD-828(FDC); S-amlodipine/telmisartan; Telminuvo Tab; Telmisartan/S-amlodipine; TelmunivoLatest Information Update: 14 Nov 2023
Price :
$50 *
At a glance
- Originator Chong Kun Dang
- Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Nicotinic acids; Small molecules
- Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 27 Sep 2023 Chong Kun Dang Pharmaceutical completes a phase I trial in Hypertension (In Volunteers) in South Korea (PO, Tablet) (NCT05881707)
- 26 Jul 2023 Chong Kun Dang Pharmaceutical completes a phase I pharmacokinetics and safety trial in healthy adult volunteers in South Korea (PO, Tablet) (NCT05834595)
- 04 Jul 2023 Chong Kun Dang Pharmaceutical initiates a phase I trial in Hypertension (In Volunteers) in South Korea (PO, Tablet) (NCT05881707)